Stem cells as drug delivery methods: Application of stem cell secretome for regeneration

Advanced Drug Delivery Reviews

Volumn 82, Issue , 2015, Pages 1-11

  Tran, Christine ^a   Damaser, Margot S ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Mechanism of action; Mesenchymal stem cells; Regenerative medicine; Secretions; Systemic therapy; Tissue engineering

Indexed keywords

BIOACTIVITY; CELL CULTURE; CELL DEATH; CELL ENGINEERING; CELL PROLIFERATION; CONTROLLED DRUG DELIVERY; FLOWCHARTING; FUNCTIONAL POLYMERS; MOLECULES; PROTEINS; PROTEOMICS; REGENERATIVE MEDICINE; TARGETED DRUG DELIVERY; TISSUE; TISSUE ENGINEERING;

CLINICAL APPLICATION; MECHANISM OF ACTION; MESENCHYMAL STEM CELL; PHYSIOLOGICAL PROCESS; SECRETIONS; SYSTEMIC THERAPY; TECHNOLOGICAL ADVANCES; THERAPEUTIC POTENTIALS;

STEM CELLS;

ADIPONECTIN; FOLLISTATIN; NANOFIBER; PLACEBO; PROTEINASE; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETORY LEUKOPROTEASE; UNCLASSIFIED DRUG;

ADIPOSE DERIVED STEM CELL; ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; BRAIN ISCHEMIA; CANCER STEM CELL; CELL HOMING; CEREBROVASCULAR ACCIDENT; CROHN DISEASE; CULTURE MEDIUM; DRUG EFFECT; ENGRAFTMENT; ERECTILE DYSFUNCTION; GLIOMA; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTERSTITIAL CYSTITIS; KIDNEY CANCER; KIDNEY INJURY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROGENIC BLADDER; NONHUMAN; PARACRINE SIGNALING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REGENERATIVE MEDICINE; RENAL PROTECTION; REVASCULARIZATION; REVIEW; SECRETION (PROCESS); SECRETOME; STEM CELL TRANSPLANTATION; STRESS INCONTINENCE; THERAPY EFFECT; TISSUE REPAIR; WOUND HEALING; DRUG DELIVERY SYSTEM; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES; TISSUE ENGINEERING;

DRUG DELIVERY SYSTEMS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PROTEOMICS; REGENERATIVE MEDICINE; TISSUE ENGINEERING;

EID: 84927137683     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.007     Document Type: Review

References (121)

1. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970, 3:393-403.
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
3. Kim J.H., Lee S.-R., Song Y.S., Lee H.J. Stem cell therapy in bladder dysfunction: where are we? And where do we have to go?. Biomed. Res. Int. 2013, [Epub ahead of print]. 10.1155/2013/930713.
4. Vaegler M., Lenis A.T., Daum L., Amend B., Stenzl A., Toomey P., Renninger M., Damaser M.S., Sievert K.-D. Stem cell therapy for voiding and erectile dysfunction. Nat. Rev. Urol. 2012, 9:435-447.
5. Al-Awqati Q., Oliver J.A. Stem cells in the kidney. Kidney Int. 2002, 61:387-395.
6. Chermansky C.J., Tarin T., Kwon D.-D., Jankowski R.J., Cannon T.W., de Groat W.C., Huard J., Chancellor M.B. Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology 2004, 63:780-785.
7. Cruz M., Dissaranan C., Cotleur A., Kiedrowski M., Penn M., Damaser M. Pelvic organ distribution of mesenchymal stem cells injected intravenously after simulated childbirth injury in female rats. Obstet. Gynecol. Int. 2012, [Epub ahead of print]. 10.1155/2012/612946.
8. Hathout Y. Approaches to the study of the cell secretome. Expert Rev. Proteomics 2007, 4:239-248.
9. Adamowicz J., Pokrywczynska M., Drewa T. Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials. Med. Hypotheses 2014, 82:670-673.
10. Boomsma R.A., Geenen D.L. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS ONE 2012, 7:e35685.
11. Dittmer J., Leyh B. Paracrine effects of stem cells in wound healing and cancer progression (Review). Int. J. Oncol. 2014, 44:1789-1798.
12. Lavoie J.R., Rosu-Myles M. Uncovering the secretes of mesenchymal stem cells. Biochimie 2013, 95:2212-2221.
13. Skalnikova H., Motlik J., Gadher S.J., Kovarova H. Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines. Proteomics 2011, 11:691-708.
14. Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie 2013, 95:2196-2211.
15. Stastna M., Van Eyk J.E. Investigating the secretome: lessons about the cells that comprise the heart. Circ. Cardiovasc. Genet. 2012, 5:o8-o18.
16. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. 1981, 78:7634-7638.
17. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
18. Ding D.C., Shyu W.C., Lin S.Z. Mesenchymal stem cells. Cell Transplant. 2011, 20:5-14.
19. Mills S.J., Cowin A.J., Kaur P. Pericytes, mesenchymal stem cells and the wound healing process. Cells 2013, 2:621-634.
20. Sundberg C., Ljungstrom M., Lindmark G., Gerdin B., Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol. 1993, 143:1377-1388.
21. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 2000, 28:875-884.
22. Sohni A., Verfaillie C.M. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013, [Epub ahead of print]. 10.1155/2013/130763.
23. Wynn R.F., Hart C.A., Corradi-Perini C., O'Neill L., Evans C.A., Wraith J.E., Fairbairn L.J., Bellantuono I. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004, 104:2643-2645.
24. Honczarenko M., Le Y., Swierkowski M., Ghiran I., Glodek A.M., Silberstein L.E. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006, 24:1030-1041.
25. Docheva D., Popov C., Mutschler W., Schieker M. Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J. Cell. Mol. Med. 2007, 11:21-38.
26. Rüster B., Göttig S., Ludwig R.J., Bistrian R., Müller S., Seifried E., Gille J., Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
27. Teo G.S., Ankrum J.A., Martinelli R., Boetto S.E., Simms K., Sciuto T.E., Dvorak A.M., Karp J.M., Carman C.V. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 2012, 30:2472-2486.
28. Ghadge S.K., Muhlstedt S., Ozcelik C., Bader M. SDF-1alpha as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol. Ther. 2011, 129:97-108.
29. Fu Q., Song X.-F., Liao G.-L., Deng C.-L., Cui L. Myoblasts differentiated from adipose-derived stem cells to treat stress urinary incontinence. Urology 2010, 75:718-723.
30. Kim S.-O., Na H.S., Kwon D., Joo S.Y., Kim H.S., Ahn Y. Bone-marrow-derived mesenchymal stem cell transplantation enhances closing pressure and leak point pressure in a female urinary incontinence rat model. Urol. Int. 2010, 86:110-116.
31. Lin G., Wang G., Banie L., Ning H., Shindel A.W., Fandel T.M., Lue T.F., Lin C.-S. Treatment of stress urinary incontinence with adipose tissue-derived stem cells. Cytotherapy 2010, 12:88-95.
32. Eggenhofer E., Benseler V., Kroemer A., Popp F.C., Geissler E.K., Schlitt H.J., Baan C.C., Dahlke M.H., Hoogduijn M.J. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 2012, 3:297.
33. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105:93-98.
34. Song Y.S., Lee H.J., Doo S.H., Lee S.J., Lim I., Chang K.-T., Kim S.U. Mesenchymal stem cells overexpressing hepatocyte growth factor (HGF) inhibit collagen deposit and improve bladder function in rat model of bladder outlet obstruction. Cell Transplant. 2012, 21:1641-1650.
35. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008, 103:1204-1219.
36. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10:244-258.
37. Katsuda T., Kosaka N., Takeshita F., Ochiya T. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics 2013, 13:1637-1653.
38. van Vliet C., Thomas E.C., Merino-Trigo A., Teasdale R.D., Gleeson P.A. Intracellular sorting and transport of proteins. Prog. Biophys. Mol. Biol. 2003, 83:1-45.
39. Nickel W., Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat. Rev. Mol. Cell Biol. 2009, 10:148-155.
40. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., Ratajczak M.Z. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20:847-856.
41. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
42. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
43. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., Geuze H.J. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183:1161-1172.
44. Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., Flament C., Pouzieux S., Faure F., Tursz T., Angevin E., Amigorena S., Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001, 7:297-303.
45. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., Squarcina P., Accornero P., Lozupone F., Lugini L., Stringaro A., Molinari A., Arancia G., Gentile M., Parmiani G., Fais S. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 2002, 195:1303-1316.
46. Higginbotham J.N., Demory Beckler M., Gephart J.D., Franklin J.L., Bogatcheva G., Kremers G.J., Piston D.W., Ayers G.D., McConnell R.E., Tyska M.J., Coffey R.J. Amphiregulin exosomes increase cancer cell invasion. Curr. Biol. 2011, 21:779-786.
47. Biernat W., Huang H., Yokoo H., Kleihues P., Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 2004, 14:131-136.
48. van Balkom B.W., Pisitkun T., Verhaar M.C., Knepper M.A. Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 2011, 80:1138-1145.
49. Ibrahim A.G., Cheng K., Marban E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Rep. 2014, 2:606-619.
50. Xin H., Li Y., Buller B., Katakowski M., Zhang Y., Wang X., Shang X., Zhang Z.G., Chopp M. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 2012, 30:1556-1564.
51. Maeshima Y., Makino H. Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair 2010, 3:13.
52. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
53. Kinnaird T., Stabile E., Burnett M.S., Shou M., Lee C.W., Barr S., Fuchs S., Epstein S.E. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004, 109:1543-1549.
54. Hung S.C., Pochampally R.R., Chen S.C., Hsu S.C., Prockop D.J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25:2363-2370.
55. Wu Y., Chen L., Scott P.G., Tredget E.E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007, 25:2648-2659.
56. Chen X., Lin X., Zhao J., Shi W., Zhang H., Wang Y., Kan B., Du L., Wang B., Wei Y., Liu Y., Zhao X. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther. 2008, 16:749-756.
57. Estrada R., Li N., Sarojini H., An J., Lee M.J., Wang E. Secretome from mesenchymal stem cells induces angiogenesis via Cyr61. J. Cell. Physiol. 2009, 219:563-571.
58. De Luca A., Gallo M., Aldinucci D., Ribatti D., Lamura L., D'Alessio A., De Filippi R., Pinto A., Normanno N. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J. Cell. Physiol. 2011, 226:2131-2138.
59. Rehman J., Traktuev D., Li J., Merfeld-Clauss S., Temm-Grove C.J., Bovenkerk J.E., Pell C.L., Johnstone B.H., Considine R.V., March K.L. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-1298.
60. Choi M., Lee H.S., Naidansaren P., Kim H.K., Cha E.O.J.H., Ahn H.Y., Yang P.I., Shin J.C., Joe Y.A. Proangiogenic features of Wharton's jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels. Int. J. Biochem. Cell Biol. 2013, 45:560-570.
61. Kim S.W., Zhang H.Z., Kim C.E., Kim J.M., Kim M.H. Amniotic mesenchymal stem cells with robust chemotactic properties are effective in the treatment of a myocardial infarction model. Int. J. Cardiol. 2013, 168:1062-1069.
62. Burlacu A., Grigorescu G., Rosca A.M., Preda M.B., Simionescu M. Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells Dev. 2013, 22:643-653.
63. Hsieh J.Y., Wang H.W., Chang S.J., Liao K.H., Lee I.H., Lin W.S., Wu C.H., Lin W.Y., Cheng S.M. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS ONE 2013, 8:e72604.
64. Liu G., Pareta R.A., Wu R., Shi Y., Zhou X., Liu H., Deng C., Sun X., Atala A., Opara E.C., Zhang Y. Skeletal myogenic differentiation of urine-derived stem cells and angiogenesis using microbeads loaded with growth factors. Biomaterials 2013, 34:1311-1326.
65. Sharma A.K., Bury M.I., Fuller N.J., Marks A.J., Kollhoff D.M., Rao M.V., Hota P.V., Matoka D.J., Edassery S.L., Thaker H., Sarwark J.F., Janicki J.A., Ameer G.A., Cheng E.Y. Cotransplantation with specific populations of spina bifida bone marrow stem/progenitor cells enhances urinary bladder regeneration. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4003-4008.
66. Ryan J.M., Barry F.P., Murphy J.M., Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond.) 2005, 2:8.
67. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
68. Liang X., Ding Y., Zhang Y., Tse H.F., Lian Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplant. 2013, 23:1045-1059.
69. Duijvestein M., van den Brink G.R., Hommes D.W. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. J. Crohn's Colitis 2008, 2:99-106.
70. Ball L.M., Bernardo M.E., Roelofs H., van Tol M.J., Contoli B., Zwaginga J.J., Avanzini M.A., Conforti A., Bertaina A., Giorgiani G., Jol-van der Zijde C.M., Zecca M., Le Blanc K., Frassoni F., Egeler R.M., Fibbe W.E., Lankester A.C., Locatelli F. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br. J. Haematol. 2013, 163:501-509.
71. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., Gerstenblith G., DeMaria A.N., Denktas A.E., Gammon R.S., Hermiller J.B., Reisman M.A., Schaer G.L., Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:2277-2286.
72. Telukuntla K.S., Suncion V.Y., Schulman I.H., Hare J.M. The advancing field of cell-based therapy: insights and lessons from clinical trials. J. Am. Heart Assoc. 2013, 2:e000338.
73. Li B., Zhang H., Zeng M., He W., Li M., Huang X., Deng D.Y., Wu J. Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharide-induced apoptosis partially by inhibiting the Wnt/beta-catenin pathway. Cell Biol. Int. 2014, [Epub ahead of print]. 10.1002/cbin.10359.
74. Tang Y.L., Zhao Q., Qin X., Shen L., Cheng L., Ge J., Phillips M.I. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann. Thorac. Surg. 2005, 80:229-236. (discussion 236-227).
75. Mangi A.A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J.S., Dzau V.J. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 2003, 9:1195-1201.
76. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., Mu H., Melo L.G., Pratt R.E., Ingwall J.S., Dzau V.J. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006, 20:661-669.
77. Salgado A.J., Reis R.L., Sousa N.J., Gimble J.M. Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Curr. Stem Cell Res. Ther. 2010, 5:103-110.
78. Drago D., Cossetti C., Iraci N., Gaude E., Musco G., Bachi A., Pluchino S. The stem cell secretome and its role in brain repair. Biochimie 2013, 95:2271-2285.
79. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 2003, 171:3426-3434.
80. Lee M.J., Kim J., Kim M.Y., Bae Y.S., Ryu S.H., Lee T.G., Kim J.H. Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J. Proteome Res. 2010, 9:1754-1762.
81. Sze S.K., de Kleijn D.P., Lai R.C., Khia Way Tan E., Zhao H., Yeo K.S., Low T.Y., Lian Q., Lee C.N., Mitchell W., El Oakley R.M., Lim S.K. Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol. Cell. Proteomics 2007, 6:1680-1689.
82. Uemura R., Xu M., Ahmad N., Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ. Res. 2006, 98:1414-1421.
83. Noiseux N., Gnecchi M., Lopez-Ilasaca M., Zhang L., Solomon S.D., Deb A., Dzau V.J., Pratt R.E. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol. Ther. 2006, 14:840-850.
84. Shabbir A., Zisa D., Suzuki G., Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1888-H1897.
85. Timmers L., Lim S.K., Hoefer I.E., Arslan F., Lai R.C., van Oorschot A.A., Goumans M.J., Strijder C., Sze S.K., Choo A., Piek J.J., Doevendans P.A., Pasterkamp G., de Kleijn D.P. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res. 2011, 6:206-214.
86. He W., Zhang L., Ni A., Zhang Z., Mirotsou M., Mao L., Pratt R.E., Dzau V.J. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21110-21115.
87. Zimmerlin L., Park T.S., Zambidis E.T., Donnenberg V.S., Donnenberg A.D. Mesenchymal stem cell secretome and regenerative therapy after cancer. Biochimie 2013, 95:2235-2245.
88. Zhu W., Huang L., Li Y., Qian H., Shan X., Yan Y., Mao F., Wu X., Xu W.R. Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth. Cell Cycle 2011, 10:3198-3207.
89. Maestroni G.J., Hertens E., Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell. Mol. Life Sci. 1999, 55:663-667.
90. Zhu Y., Sun Z., Han Q., Liao L., Wang J., Bian C., Li J., Yan X., Liu Y., Shao C., Zhao R.C. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009, 23:925-933.
91. Sherry M.M., Reeves A., Wu J.K., Cochran B.H. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009, 27:2383-2392.
92. Wei J., Barr J., Kong L.Y., Wang Y., Wu A., Sharma A.K., Gumin J., Henry V., Colman H., Sawaya R., Lang F.F., Heimberger A.B. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 2010, 16:461-473.
93. Grange C., Tapparo M., Collino F., Vitillo L., Damasco C., Deregibus M.C., Tetta C., Bussolati B., Camussi G. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71:5346-5356.
94. Ye H., Cheng J., Tang Y., Liu Z., Xu C., Liu Y., Sun Y. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Investig. 2012, 30:513-518.
95. Bi B., Schmitt R., Israilova M., Nishio H., Cantley L.G. Stromal cells protect against acute tubular injury via an endocrine effect. J. Am. Soc. Nephrol. 2007, 18:2486-2496.
96. van Koppen A., Joles J.A., van Balkom B.W., Lim S.K., de Kleijn D., Giles R.H., Verhaar M.C. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS ONE 2012, 7:e38746.
97. Wang Y., Bakota E., Chang B.H., Entman M., Hartgerink J.D., Danesh F.R. Peptide nanofibers preconditioned with stem cell secretome are renoprotective. J. Am. Soc. Nephrol. 2011, 22:704-717.
98. Bakota E.L., Wang Y., Danesh F.R., Hartgerink J.D. Injectable multidomain peptide nanofiber hydrogel as a delivery agent for stem cell secretome. Biomacromolecules 2011, 12:1651-1657.
99. Dissaranan C., Cruz M.A., Kiedrowski M.J., Balog B.M., Gill B.C., Penn M.S., Goldman H.B., Damaser M.S. Rat mesenchymal stem cell secretome promotes elastogenesis and facilitates recovery from simulated childbirth injury. Cell Transplant. 2013, 23:1395-1406.
100. Zhang H., Qiu X., Shindel A.W., Ning H., Ferretti L., Jin X., Lin G., Lin C.S., Lue T.F. Adipose tissue-derived stem cells ameliorate diabetic bladder dysfunction in a type II diabetic rat model. Stem Cells Dev. 2012, 21:1391-1400.
101. Albersen M., Fandel T.M., Lin G., Wang G., Banie L., Lin C.S., Lue T.F. Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J. Sex. Med. 2010, 7:3331-3340.
102. Yu S.P., Wei Z., Wei L. Preconditioning strategy in stem cell transplantation therapy. Transl. Stroke Res. 2013, 4:76-88.
103. Togel F., Weiss K., Yang Y., Hu Z., Zhang P., Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am. J. Physiol. Ren. Physiol. 2007, 292:F1626-F1635.
104. Chang C.P., Chio C.C., Cheong C.U., Chao C.M., Cheng B.C., Lin M.T. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin. Sci. 2013, 124:165-176.
105. Tang Y.L., Zhu W., Cheng M., Chen L., Zhang J., Sun T., Kishore R., Phillips M.I., Losordo D.W., Qin G. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ. Res. 2009, 104:1209-1216.
106. Yagi H., Soto-Gutierrez A., Navarro-Alvarez N., Nahmias Y., Goldwasser Y., Kitagawa Y., Tilles A.W., Tompkins R.G., Parekkadan B., Yarmush M.L. Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Mol. Ther. 2010, 18:1857-1864.
107. Sakata H., Narasimhan P., Niizuma K., Maier C.M., Wakai T., Chan P.H. Interleukin 6-preconditioned neural stem cells reduce ischaemic injury in stroke mice. Brain 2012, 135:3298-3310.
108. Frith J.E., Thomson B., Genever P.G. Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential. Tissue Eng. C Methods 2010, 16:735-749.
109. Ylostalo J.H., Bartosh T.J., Coble K., Prockop D.J. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 2012, 30:2283-2296.
110. Bartosh T.J., Ylostalo J.H., Mohammadipoor A., Bazhanov N., Coble K., Claypool K., Lee R.H., Choi H., Prockop D.J. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13724-13729.
111. Lan F., Liu J., Narsinh K.H., Hu S., Han L., Lee A.S., Karow M., Nguyen P.K., Nag D., Calos M.P., Robbins R.C., Wu J.C. Safe genetic modification of cardiac stem cells using a site-specific integration technique. Circulation 2012, 126:S20-S28.
112. Gropp M., Reubinoff B. Lentiviral vector-mediated gene delivery into human embryonic stem cells. Methods Enzymol. 2006, 420:64-81.
113. Xiong N., Zhang Z., Huang J., Chen C., Zhang Z., Jia M., Xiong J., Liu X., Wang F., Cao X., Liang Z., Sun S., Lin Z., Wang T. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther. 2011, 18:394-402.
114. Bakshi A., Shimizu S., Keck C.A., Cho S., LeBold D.G., Morales D., Arenas E., Snyder E.Y., Watson D.J., McIntosh T.K. Neural progenitor cells engineered to secrete GDNF show enhanced survival, neuronal differentiation and improve cognitive function following traumatic brain injury. Eur. J. Neurosci. 2006, 23:2119-2134.
115. Yamane J., Nakamura M., Iwanami A., Sakaguchi M., Katoh H., Yamada M., Momoshima S., Miyao S., Ishii K., Tamaoki N., Nomura T., Okano H.J., Kanemura Y., Toyama Y., Okano H. Transplantation of galectin-1-expressing human neural stem cells into the injured spinal cord of adult common marmosets. J. Neurosci. Res. 2010, 88:1394-1405.
116. Yang J., Jiang Z., Fitzgerald D.C., Ma C., Yu S., Li H., Zhao Z., Li Y., Ciric B., Curtis M., Rostami A., Zhang G.X. Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis. J. Clin. Invest. 2009, 119:3678-3691.
117. Mirotsou M., Jayawardena T.M., Schmeckpeper J., Gnecchi M., Dzau V.J. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J. Mol. Cell. Cardiol. 2011, 50:280-289.
118. Kang H.J., Kim H.S., Zhang S.Y., Park K.W., Cho H.J., Koo B.K., Kim Y.J., Soo Lee D., Sohn D.W., Han K.S., Oh B.H., Lee M.M., Park Y.B. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004, 363:751-756.
119. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., Rovner A., Ellis S.G., Thomas J.D., DiCorleto P.E., Topol E.J., Penn M.S. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
120. Beohar N., Rapp J., Pandya S., Losordo D.W. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J. Am. Coll. Cardiol. 2010, 56:1287-1297.
121. Ribeiro C.A., Salgado A.J., Fraga J.S., Silva N.A., Reis R.L., Sousa N. The secretome of bone marrow mesenchymal stem cells-conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures). J. Tissue Eng. Regen. Med. 2011, 5:668-672.